ENO2 and nonpapillary renal cell carcinoma: Moreover, compared with patients in the low-risk group, ccRCC patients in the high-risk group exhibited higher expression of RPIA, G6PD, PSAT1, ENO2, HK3, and IDH1 and lower expression of PDK4, PGM2, PGK1, FBP1, OGDH, SUCLA2, and SUCLG2 (Figures 7(c) and 7(h)).